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Background: Inhaled corticosteroid therapy suppresses nitric oxide levels (NO) of airway origin but
not necessarily NO of alveolar or small airway origin. Systemic therapywith an oral anti-leukotriene
agent may suppress NO production in distal airways and alveoli not reached by inhaled therapy.
Methods: Adult patients withmild asthmawere treated for 3 weeks with inhaled fluticasone 250 mg
twice daily then with inhaled fluticasone plus oral montelukast 10 mg daily for 3 additional weeks.
WemonitoredexhaledNO(eNO), spirometry, lungvolumes,andasthmasymptomsscoresatbaseline
and at the end of each treatment period. In a subset of patients, we continued with montelukast
monotherapy and repeated these measurements.
Results: In the 18 patients studied, pulmonary function parameters and asthma symptom scores
were not altered significantly from baseline by any therapy. The total eNO at baseline was
55  35.3 ppb, dropping to 28.1  15.3 ppb (pZ 0.005) after 3 weeks of fluticasone and to
23.5 14 ppb (pZ 0.001vs.baseline) after theadditionofmontelukast.The trend towards reduced
total eNO with the combination therapy vs. monotherapy was not statistically significant. Alveolar
eNO dropped from 4.2  2.4 at baseline to 3.0  1.5 (pZ 0.1) after fluticasone and then to
2.2 0.9 (pZ 0.08 vs. baseline) after fluticasone plus montelukast, increasing then to 3.8 1.8
after montelukast alone (pZ 0.6 vs. baseline).
Conclusions: Leukotriene receptor antagonists administered systemically might decrease small
airway/alveolar sites of inflammation when combined to inhaled corticosteroid therapy.
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Montelukast and eNO in corticosteroid-treated asthma 297Introduction Study populationRecent studies have redirected attention to the role of the
small airways and alveoli in asthma. Studies using resected
lung tissue, autopsy specimens and transbronchial biopsy
specimens have shown inflammatory and structural changes
in the small airways are comparable to those within the
central airways.1e5 Moreover, the severity of these
peripheral changes has been correlated with disease
instability, resistance to therapy and excessive airway
narrowing.4,6,7
For research purposes, the small airways and alveoli can
be assessed via transbronchial biopsy, although the inva-
siveness of this approach rules out its routine clinical use.
Non-invasive physiologic studies of the small airway are
easier to perform, but are limited by their testeretest
variability and or lack of specificity in reflecting small
airways function. High resolution computed tomography
has also been used to assess signs of peripheral airway
compromise indirectly but radiation exposure limits its
usefulness in the clinical setting.8
Measurement of exhaled nitric oxide (eNO) is a relatively
simple, non-invasive test for monitoring endogenous
inflammatory signals and responses to therapy in asthma.9e12
Tsoukias and George have developed a two-compartment
model that has been used to quantify separately the amounts
of eNO arising from the proximal airways and alveoli.13,14
Studies have shown increased levels of both bronchial and
alveolar eNO in asthma with the latter correlated with
bronchoalveolar lavage eosinophil cationic protein levels
and total eosinophil count.15e18 Alveolar eNO as a parameter
is reproducible, does not vary diurnally and can bemeasured
in all asthmatic patients capable of simple breathing
maneuvers.19
There is evidence that in at least some patients with
asthma, inhaled therapy does not suppress alveolar eNO
levels and that suppressing this inflammation may require
systemic corticosteroid therapy. Montelukast, a systemi-
cally delivered leukotriene receptor antagonist may exert
effects on both small and large airways.20 In this prospec-
tive study we evaluated the impact of montelukast added
to fluticasone on bronchial and alveolar sites of
inflammation.Methods
Study design
This was a six (phase 1) to nine (phase 2) week open-label
study in which the primary endpoint was to determine
whether the addition of montelukast to inhaled fluticasone
could result in further suppression of alveolar and bronchial
eNO levels. In a subset of subjects, we evaluated the
impact of fluticasone alone, montelukast alone and both
medications combined in the alveolar and bronchial eNO
levels. Secondary endpoints were to assess the effects of
fluticasone and montelukast on total eNO levels, lung
function tests and asthma symptoms.
The study was approved by the Ethics Committee of the
Institutional Review Board Services.Mild non-smokers asthmatics, 18e75 years of age, previ-
ously shown to have reversible airflow limitation on
pulmonary function test (12%) or a positive methacholine
challenge (PC20 8 mg/ml), with baseline spirometry
measurements within normal limits (FEV1 80% of pre-
dicted). Subjects were not being treated with inhaled
corticosteroids, anti-leukotriene agents or other anti-
inflammatory asthma medications for a period of at least 3
months and were required to have baseline eNO levels
greater than 20 ppb.
Study description
The eNO measurement was done using a Sievers NOA 280
chemiluminescence analyzer with varying expiratory
airflow resistance.
Phase 1
At visit 1 (baseline), subjects answered the Asthma Control
Questionnaire (ACQ),21 had pulmonary function measure-
ments including diffusing capacity (DLco), spirometry
(FEV1, FVC), lung volumes by plethysmography (FRC, IC)
and total airways resistance (Raw), followed by post-
bronchodilator response and baseline eNO measurement
(eNO at 50 ml/s).22
The subjects were then treated with inhaled fluticasone
250 mg twice daily (Flovent 125 MDI, GlaxoSmithKlein, two
puffs twice daily) for 3 weeks and returned for visit 2, when
measurements for alveolar and bronchial eNO calculation
were taken. Exhaled eNO was measured at five separate
constant expiratory flow rates: 50, 100, 150, 200 and
250 ml/s in triplicate, and the mean of three values
obtained within 10% of each other. The technique of
Tsoukias and George was used to calculate bronchial eNO
maximal flux alveolar NO concentration. Post-bronchodi-
lator pulmonary function test was performed and ACQ was
administered.13,14
Subsequently, the subjects were treated with inhaled
fluticasone 250 mg twice daily plus montelukast 10 mg daily
(Singulair 10 mg, Merck) for further 3 weeks, and returned
for visit 3, when the same measurements of visit 2 were
performed.
Phase 2
For the last 7 subjects enrolled in the study, alveolar and
bronchial NO were evaluated at baseline, prior to treat-
ment with fluticasone, as well as at the subsequent visits.
They received 3 weeks of fluticasone treatment followed by
3 weeks of fluticasone and montelukast. They subsequently
were treated with 3 weeks of montelukast alone. Fig. 1
illustrates the study design.
Statistical analysis
Normally distributed variables were described as means and
standard deviations. Non-normally distributed variables were
described asmedians (ranges). The comparison of quantitative
data was carried out using Student’s t-test for paired samples.
Tukey’s testwascarriedout formultiplecomparisons.Thedata
were analyzed with SAS and SigmaPlot (version 8.0).
Figure 1 Study design.
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Eighteen subjects entered and completed the protocol.
Seven subjects participated in the extended protocol
(phase 2). Baseline characteristics are shown in Table 1.
The post-bronchodilator FEV1 was unchanged after flu-
ticasone treatment and after fluticasone plus montelukast.
The mean ACQ score dropped non-significantly from
4.4 3.8 in visit 1 to 3.0 2.8 in visit 2 (pZ 0.24) and to
3.0 3.7 in visit 3 (pZ 0.28).
For the total cohort of 18 subjects, the baseline eNO at
50 ml/s was 55 35.3, dropping to 28.1 15.3, a 50%
reduction (pZ 0.005 vs. baseline) after 3 weeks of fluti-
casone and to 23.5 14 ppb, a further 10% reduction
(pZ 0.001 vs. baseline) after the addition of montelukast
(Fig. 2). The reduction observed from visit 2 to 3 was not
statistically significant (pZ 0.35). Alveolar NO concentra-
tion measured after 3 weeks of fluticasone was 2.3 1.8
dropping to 1.8 1.5 ppb (pZ 0.3) after montelukast was
added. Bronchial NO maximal flux was 1.28 0.73 after
fluticasone and 1.06 0.69 nL/s (pZ 0.2).
For the 7 subjects who participated in phase 2 (for whom
we had measurements of alveolar and bronchial NO from
baseline), the alveolar NO dropped 25%, from 4.2 2.4 at
baseline to 3.0 1.5 (pZ 0.1 vs. baseline) after fluticasone
and then further 25% to 2.2 0.9 (pZ 0.08 vs. baseline)
after fluticasone plus montelukast, increasing then to
3.8 1.8 after montelukast alone (pZ 0.6 vs. baseline), as
shown in Fig. 3. The bronchial NO flux showed a 50%
reduction, from 2.8 1.4 at baseline to 1.4 0.8
(pZ 0.005 vs. baseline) after fluticasone and then further
7%, to 1.2 0.9 (pZ 0.008 vs. baseline) after fluticasone
plus montelukast (Fig. 4), increasing then to 2.0 1.3 afterTable 1 Baseline characteristics.
Age, yr 39.3 11
Female sex, n (%) 9 (50)
FEV1% pre-BD 87.3% 18.2
FVC% pre-BD 104.8% 14.7
FEV1/FVC pre-BD 70.5% 12.2
FEV1% post-BD 97.5% 12.4
FVC% post-BD 108% 12.9
FEV1/FVC post-BD 75.8% 9.5
Asthma control questionnaire 4.4 3.8montelukast alone (pZ 0.051 vs. baseline). For this
subgroup, similar reductions in the eNO at 50 ml/s were
observed when compared to what was seen for the whole
cohort of 18 subjects (from 61.3 28.8 at baseline to
31.6 17.2 after fluticasone, pZ 0.038; and 26.0 19.8
after fluticasone and montelukast, pZ 0.02).
Discussion
In our study of patients with mild asthma, we found that
total exhaled nitric oxide values were suppressed by the
inhalation of inhaled fluticasone and that the addition of
oral montelukast showed modest and non-significant addi-
tional benefit. However, in a subset of subjects, when we
partitioned exhaled nitric oxide values into bronchial and
alveolar compartments, we found that that the combina-
tion of inhaled fluticasone and oral montelukast caused
a more significant suppression in the alveolar than in the
total and bronchial nitric oxide levels. Such findings suggest
that the use of a systemic anti-inflammatory may have
particular benefit in suppression of distal airway andFigure 2 Exhaled nitric oxide levels (eNO). Flut, fluticasone;
montel, montelukast.
Figure 3 Alveolar nitric oxide levels (alveolar eNO). Flut,
fluticasone; montel, montelukast.
Figure 4 Bronchial nitric oxide flux levels (bronchial eNO).
Flut, fluticasone; montel, montelukast.
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inhaled anti-inflammatory medication alone.
It is unclear whether inhaled corticosteroids are effica-
cious in treating the small airways. Deposition studies have
demonstrated that most of the currently used inhaled
corticosteroids are deposited predominantly in the central
airways and not in the lung periphery although this may not
be true of newer hydrofluoroalkane (HFA) formulation
agents.23,24 Lethimaki and coworkers found that fluticasone
administered via diskus device was able to reduce bronchial
but not alveolar NO in mild asthmatics.17 If inhaled corti-
costeroids fail to treat the more peripheral airways, it has
been suggested that systemic medications could do so. Gelb
and colleagues found that 5 days of 30 mg of oral predni-
sone suppressed the alveolar nitric oxide to near-normal
levels,10 while Berry et al. also found a significant alveolar
NO improvement after oral corticosteroids, but not by
doubling the dose of inhaled steroids.18
Previous investigations have demonstrated a peripheral
airway effect of montelukast. Zeidler et al. have showed
that montelukast treatment resulted in significantly less
regional air-trapping on high resolution computed tomog-
raphy images when compared with placebo, as well as
improvement in total quality of life scores.25 More recently,
Kraft and colleagues demonstrated that montelukast
caused a reduction in residual volume, which was used as
a marker of peripheral airway disease, and this was signif-
icantly correlated with symptomatic improvement.26
In our study, treatment with fluticasone caused an
approximate 50% reduction in bronchial eNO flux, and the
addition of montelukast was associated with a further 7%
decrease. For alveolar NO, fluticasone alone did not cause
such an impressive reduction, decreasing it by 25%;
a further 25% reduction was achieved only when mon-
telukast was added, suggesting that its addition effect on
asthma treatment might be its action in the peripheral
airways. On the other hand, once this subset of asthmaticswere treated with montelukast alone, there were no
significant differences when compared to the baseline
results, perhaps because the effects of this medication
alone are small or because its effect is enhanced by co
treatment with inhaled corticosteroids.
Some limitations to our study should be noted. It was
opened-label, non-controlled pilot study in a relatively
small number of patients. Some of the non-significant
trends we observed could have proved to be significant in
a larger population. Furthermore, a pre-post study design
may be biased by regression to the mean. We must also
note that in our design, montelukast was added to flutica-
sone; we cannot exclude the possibility that further
improvements were the result of a longer period of treat-
ment with inhaled corticosteroid rather than the addition
of a second medication.
Our findings support the hypothesis that leukotriene
receptor antagonists administered systemically might
decrease small airway/alveolar sites of inflammation, when
added to inhaled corticosteroid therapy, and this effect
seems to be greater than to either drugs alone. Further
studies will be needed to determine the biological and
clinical significance of these findings.
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